Pharmaceutical Mild cognitive impairment (MCI) is under the pharmaceutical spotlight as the number of clinical trials currently underway has increased significantly during the past 12 months and the search for treatments that will prevent the progression of MCI to dementia continues. Synexus, a UK-based patient recruitment and trial management business, has teamed up with dementia expert, Roger Bullock, to develop more effective clinical trials for this field. 16 November 2010